lutetium (<sup>177</sup>Lu) zadavotide guraxetan
Prostate Cancer
Jonsson Comprehensive Cancer CenterOtherPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 59/ 100
Competitive context
513 Active assets in the Prostate Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Avodart Bay State Clinical Trials, Inc. | Phase 4 | BBB |
Desflurane Peter MacCallum Cancer Centre, Australia | Phase 4 | BBB |
PROPOFOL Peter MacCallum Cancer Centre, Australia | Phase 4 | BBB |
Degarelix Bayer | Phase 4 | BBB |
Flotufolastat F-18 Washington University School of Medicine | Phase 4 | BB |
View all 50 →
Same molecule, other indications
lutetium (<sup>177</sup>Lu) zadavotide guraxetan is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →